Inventor · disambiguated record
Li Ren
Also filed as: REN LI · Ren li qun
44 granted patents·20 pending applications·175 citations·filing 2006–2025
97Inventor score
Top patents by PatentIndex Score
64 records- 0198US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0297US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 0397US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 0496US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 0596US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 0694US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 0794US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 0893US8697715B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2013·Granted Apr 15, 2014·21 cites·25 claims
- 0991US10172845B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·4 cites·29 claims
- 1090US11807638B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2022·Granted Nov 7, 2023·1 cites·44 claims
- 1189US11802127B23,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitorsPFIZER·Filed 2022·Granted Oct 31, 2023·1 cites·53 claims
- 1289US10144734B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 4, 2018·6 cites·30 claims
- 1388US10441581B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Oct 15, 2019·2 cites·29 claims
- 1487US11998545B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2023·Granted Jun 4, 2024·0 cites·14 claims
- 1585US11767321B25- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinasesENLIVEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·31 claims
- 1685US9763942B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Sep 19, 2017·5 cites·18 claims
- 1785US9259470B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Feb 16, 2016·6 cites·45 claims
- 1883US9708290B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jul 18, 2017·3 cites·12 claims
- 1982US10881652B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Jan 5, 2021·2 cites·14 claims
- 2082US10154995B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 18, 2018·3 cites·18 claims
- 2181US12240846B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2023·Granted Mar 4, 2025·0 cites·14 claims
- 2281US9670208B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jun 6, 2017·4 cites·19 claims
- 2380US9133187B2Serine/threonine kinase inhibitorsBLAKE JAMES F·Filed 2012·Granted Sep 15, 2015·6 cites·20 claims
- 2480US2023090520A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2577US8394795B2Pyrazole [3, 4-B] pyridine Raf inhibitorsAHRENDT KATERI A·Filed 2009·Granted Mar 12, 2013·5 cites·45 claims
- 2676US11691973B23,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitorsPFIZER·Filed 2022·Granted Jul 4, 2023·0 cites·11 claims
- 2776US8338452B2Raf inhibitor compounds and methods of use thereofAHRENDT KATERI A·Filed 2009·Granted Dec 25, 2012·4 cites·49 claims
- 2876US2021186959A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2975US2024002384A13,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitorsPFIZER·Filed 2023·Application pending·0 cites
- 3073US2025236621A15- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN INC·Filed 2025·Application pending·0 cites
- 3172US11648243B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted May 16, 2023·0 cites·20 claims
- 3271US11634409B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2022·Granted Apr 25, 2023·0 cites·42 claims
- 3371US2025263411A13,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitorsPFIZER·Filed 2025·Application pending·0 cites
- 3469US11851434B2Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Granted Dec 26, 2023·0 cites·16 claims
- 3568US12303509B2Compounds for the treatment of BRAF-associated diseases and disordersPFIZER·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 3666US11807649B2Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2ENLIVEN THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·0 cites·44 claims
- 3766US2024228486A1Sulfone- and sulfoximine-based selective parp1 inhibitorsENLIVEN INC·Filed 2023·Application pending·0 cites
- 3865US10766881B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·21 claims
- 3965US2023382923A1Fused tetracyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4063US10934345B2Broadly neutralizing antibodies against HIV-1 and use thereofNAT CENTER FOR AIDS/STD CONTROL & PREVENTION CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION·Filed 2017·Granted Mar 2, 2021·1 cites·19 claims
- 4162US2025241915A1Compounds for the treatment of braf-associated diseases and disordersPFIZER·Filed 2025·Application pending·0 cites
- 4259US2024287062A1Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinasesENLIVEN INC·Filed 2022·Application pending·0 cites
- 4358US10519126B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 31, 2019·0 cites·4 claims
- 4457US2025136595A1Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN INC·Filed 2022·Application pending·0 cites
- 4554US12113208B2Protective membrane for electrochemical cellsSION POWER CORP·Filed 2018·Granted Oct 8, 2024·0 cites·23 claims
- 4653US12351571B2Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Jul 8, 2025·0 cites·12 claims
- 4751US11168090B2Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 9, 2021·0 cites·12 claims
- 4851US2024116921A1Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4950US11603374B2Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Mar 14, 2023·0 cites·12 claims
- 5050US2024043420A17-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Li Ren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →